查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1445533

全球HPV（人類乳突病毒）疫苗市場評估：按類型、適應症、合成方法、分銷管道和地區劃分的機會和預測（2017-2031年）

Human Papillomavirus Vaccine Market Assessment, By Type, By Disease Indication, By Method of Synthesis, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 246 Pages | 商品交期: 3-5個工作天內

價格

全球 HPV（人類乳突病毒）疫苗市場規模將從 2023 年的 45.8 億美元增長到 2031 年的 91.1 億美元，2024-2031 年預測期內複合年增長率為 8.99%。預計將增長至10,000,000。

人們對HPV 疫苗接種重要性的認識不斷提高、子宮頸癌和其他與HPV 感染相關的疾病患病率上升、政府舉措和疫苗接種計劃的進步以及疫苗開發技術的進步。有幾個因素正在推動市場發展。

世界各地的政府和醫療機構正在採取積極措施，提高人們對 HPV 疫苗接種益處的認識，並開展針對青少年的疫苗接種活動。 因此，對 HPV 疫苗的需求持續增加，這表明疫苗接種作為對抗 HPV 感染和相關疾病的重要武器越來越被接受。

此外，疫苗開發技術的進步導致了先進的HPV疫苗的推出，其功效和安全性得到提高，支持了市場的擴張。 全球HPV疫苗市場仍是製藥公司和研究機構大量投資的焦點。 目的是開發創新疫苗配方並提高可近性，以便更多人能夠從 HPV 疫苗接種中受益。

子宮頸癌盛行率高

全球 HPV 疫苗市場深受子宮頸癌盛行率的影響。 子宮頸癌是女性第四大常見癌症。 全球超過 58% 的子宮頸癌病例發生在亞洲，20% 在非洲，10% 在歐洲，10% 在拉丁美洲。 同樣，預計亞洲將佔子宮頸癌死亡人數的 58%，其次是非洲（佔 22%）、拉丁美洲（佔 9%）和其他地區。 子宮頸癌患者中18%在中國，21%在印度，死亡率在中國17%，印度23%。

增加研發投資

近年來，全球HPV疫苗市場研發投入大幅增加。 資金的激增反映出人們越來越認識到疫苗在預防 HPV 感染和相關疾病方面的重要作用。 為了推動 HPV 疫苗技術、配方和分銷的進步，世界各地的政府、製藥公司和研究機構正在出於各種目的進行合作。

本報告調查了全球HPV（人類乳突病毒）疫苗市場，提供了市場定義和概述、市場規模趨勢和預測、各個細分市場和地區的詳細分析以及影響市場成長的因素。我們編制分析、案例研究、競爭優勢景觀、主要公司簡介等等。

目錄

第 1 章研究方法

第 2 章專案範圍與定義

第 3 章執行摘要

第 4 章全球HPV（人類乳突病毒）疫苗市場展望

  • 市場規模/預測
  • 依類型
    • 二價
    • 四價
    • 九價
  • 依指示
    • 子宮頸癌
    • 肛門癌
    • 外陰癌/陰道癌
    • 陰莖癌
    • 口咽癌
    • 其他
  • 依合成法
    • 基於核酸
    • 勝□基
    • 蛋白質基礎
    • 基於細胞
    • 活載體疫苗
  • 按分銷管道
    • 醫院
    • 零售藥局
    • 政府機構
    • 非政府組織
  • 按地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美洲
    • 中東/非洲
  • 各公司的市佔率

第 5 章全球 HPV（人類乳突病毒）疫苗市場前景：依地區劃分

  • 北美
  • 歐洲
  • 亞太地區
  • 南美洲
  • 中東/非洲

第 6 章市場映射

  • 依類型
  • 依指示
  • 依合成法
  • 按分銷管道
  • 按地區

第 7 章宏觀環境與產業結構

  • 需求與供給分析
  • 匯入/匯出分析
  • 價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市場動態

  • 生長促進因素
  • 生長抑制因素（問題、限制因素）

第 9 章監理架構與創新

  • 臨床試驗
  • 專利情況
  • 監理機關的核准
  • 創新/新興技術

第 10 章主要公司狀況

  • 前 5 名市場領導者的競爭矩陣
  • 前 5 位市場領導者的市場收入分析
  • 併購/合資企業（如果適用）
  • SWOT 分析（5 家參與公司）
  • 專利分析（如果適用）

第 11 章價格分析

第 12 章案例研究

第 13 章主要公司展望

  • GlaxoSmithKline PLC.
  • Merck & Co., Inc.
  • Beijing Health Guard Biotechnology, Inc.
  • China National Biotec Group Company Limited
  • Shanghai Bovax Biotechnology Co., Ltd.
  • Walvax Biotechnology Co., Ltd
  • Xiamen Innovax Biotech Co., Ltd.
  • Serum Institute of India Pvt. Ltd.
  • Eyegene Inc.
  • Janssen Biotech, Inc.

第 14 章策略建議

第 15 章關於我們公司/免責聲明

Product Code: MX11082

Global human papillomavirus vaccine market size was valued at USD 4.58 billion in 2023 which is expected to reach USD 9.11 billion in 2031 with a CAGR of 8.99% for the forecast period between 2024 and 2031. Several factors are driving the global human papillomavirus vaccine market such as growing awareness about the importance of HPV vaccination, rising prevalence of cervical cancer and other diseases linked to HPV infection, initiatives, and vaccination programs launched by the governments, and technological advancements in vaccine development.

Governments and healthcare organizations across the globe have taken proactive steps to raise awareness about the advantages of HPV vaccination and execute vaccination campaigns, focusing on young adolescents. Consequently, the demand for HPV vaccines has consistently risen, showcasing the increasing acceptance of vaccination as a vital weapon in combatting HPV infections and related diseases.

Furthermore, the market's expansion has been bolstered by technological advancements in vaccine development, giving rise to the introduction of advanced HPV vaccines with improved efficacy and safety characteristics. The global human papillomavirus vaccine market remains a focal point for substantial investments from pharmaceutical companies and research institutions. Their objective is to develop groundbreaking vaccine formulations and enhance accessibility, ensuring that a larger population can benefit from HPV vaccination.

Nigeria incorporated the human papillomavirus (HPV) vaccine into its regular vaccination program in October 2023 to vaccinate 7.7 million girls. It is the highest number of HPV vaccinations given to patients in a single round in the African continent. The vaccine is very effective at preventing infection with HPV types 16 and 18, which are known to be the cause of at least 70% of cervical cancers, which will be given to girls between the ages of 9 and 14 in a single dosage.

High Prevalence of Cervical Cancer

The global human papillomavirus vaccine market is highly affected by the prevalence of cervical cancer. Worldwide, cervical cancer ranks as the fourth most prevalent cancer among women. More than 58% of cervical cancer cases worldwide were found in Asia, with 20% occurring in Africa, 10% in Europe, and 10% in Latin America. Similarly, it was predicted that Asia accounted for 58% of cervical cancer deaths, followed by Africa (22%), Latin America (9%), and other regions. China accounted for 18% of cervical cancer patients and India accounted for 21%, whereas mortality rates were 17% in China and 23% in India. The age-standardized incidence of cervical cancer was at its lowest in Western Asia, with 4.1 cases per 100,000 women-years.

Incidence rates were relatively low in Oceania, Northern America, and most regions of Europe, except for some countries in central and eastern Europe, such as Romania (22.6) and Bulgaria (18.0). Mortality rates showed a similar pattern to incidence, displaying significant variations across regions. Eastern Africa had the highest mortality rates at 28.6 deaths per 100,000 women years, while Western Europe reported the lowest mortality rates.

Increasing Investments in Research and Development

Over the past few years, there has been a notable increase in research and development investments in the global human papillomavirus vaccine market. The surge in funding reflects the growing recognition of the critical role these vaccines play in preventing HPV infections and associated diseases. To drive advancements in HPV vaccine technology, formulation, and distribution; governments, pharmaceutical companies, and research institutions worldwide have formed collaborations with different objectives.

The Gavi Board, in December 2022, approved the revitalization of the Alliance's HPV vaccination program, earmarking an investment of over USD 600 million by the end of 2025. With substantial funding, the Alliance has set a commendable objective of reaching more than 86 million girls by 2025 and preventing 1.4 million potential deaths from cervical cancer in the future.

Government Initiatives

Governments across the globe have acknowledged the importance of addressing the impact of cervical cancer and have initiated various initiatives to combat this virus. Initiatives taken by the government have helped in the growth of the global human papillomavirus vaccine market. Governments have implemented national cervical cancer screening programs, offering regular screening tests like pap smears or HPV testing, to detect pre-cancerous lesions in their early stages. These programs play a vital role in reducing the occurrence of cervical cancer by facilitating timely interventions. For instance, in the interim budget for 2024-2025, Union Finance Minister of India declared that the government intended to vaccinate all girls aged 9-14 against cervical cancer. It occurred more than a year after the vaccine's introduction under the Universal Vaccination Programme (UIP) was recommended by the National Technical Advisory Group on Immunization (NTAGI), the highest vaccination advisory body of the national government.

Increasing Demand for Bivalent Vaccine

Rising demand for bivalent vaccines has caused an increase in the growth of the global human papillomavirus vaccine market. The bivalent human papillomavirus (HPV) vaccine has become a pivotal weapon in the battle against cervical cancer and other HPV-related diseases. With its focus on targeting specific HPV strains responsible for a large proportion of cervical cancer cases, the vaccine has garnered considerable interest and recognition for its demonstrated efficacy and safety.

The HPV bivalent vaccine is administered to girls and young women aged 9 to 25. It is important to note that individuals can receive this vaccine even if they have previously tested positive for HPV or have had an abnormal pap smear in the past. In May 2022, China's National Medical Products Administration (NMPA) granted approval for a two-dose vaccine schedule of Cervarix, a bivalent vaccine developed by GlaxoSmithKline PLC, a British multinational pharmaceutical and biotechnology company. The approval was for the prevention of cervical cancer, cervical intraepithelial neoplasia, and adenocarcinoma in-situ linked to oncogenic Human Papillomavirus (HPV) types 16 and 18.

Growing Demand for Human Papillomavirus Vaccine for Cervical Cancer

In response to significant public health challenges, the development of HPV vaccines has emerged as a crucial preventive strategy against cervical cancer and other HPV-related illnesses, which has led to the growth of global human papillomavirus vaccine market. Their introduction of HPV vaccine has sparked significant interest in preventive healthcare, presenting a promising approach to alleviate the burden of cervical cancer and its impact. Through rigorous research and clinical trials, these vaccines have demonstrated their efficacy and safety, paving the way for their widespread incorporation into national immunization programs. Walvax Biotechnology, a Chinese drug developer, received approval to launch its recombinant bivalent human papillomavirus vaccine in China in March 2022. This vaccine has demonstrated efficacy in preventing cervical cancer caused by specific HPV strains, making it a significant milestone in the fight against human papillomavirus.

Asia-Pacific to Dominate the Market in Terms of Prevalence and Vaccination Drives

Cervical cancer is highly prevalent in Asian nations. Asia accounted for an estimated 58% of all cervical cancer cases worldwide. Several measures are being taken by governments in Asia-Pacific to address this problem. It is advised to receive the HPV vaccine as part of a comprehensive and well-coordinated plan to prevent HPV-related diseases, including cervical cancer. While India and Indonesia have implemented HPV, countries, such as Bhutan, Sri Lanka, Thailand, and Maldives have it on a national scale. HPV demonstration programs have been completed in Bangladesh and Nepal, and plans are in motion for a countrywide introduction. The introduction plans for Myanmar have been authorized. Crowell & Moring International formed the Asia-Pacific Women's Cancer Coalition in June 2023, partnering with Roche, TogetHER for Health, CAPED, and Jhpiego to increase awareness about the rise in breast and cervical cancer incidence in Asia-Pacific. To assist nations in reaching their national goals for cancer prevention and control, the coalition focuses on finding opportunities and filling up the gaps.

Future Market Scenario (2024 - 2031F)

The increased prevalence of HPV-related diseases, including cervical, anal, and oropharyngeal malignancies, is driving the demand for HPV vaccines globally.

Strategic approvals and activities to increase vaccine coverage are taking place in global human papillomavirus vaccine market.

In the global human papillomavirus vaccine market, major pharmaceutical companies are concentrating on developing new products and improving vaccination efficiency through research and development.

Cervical cancer is more prevalent in developing countries. Due to increasing urbanization, the prevalence of cervical cancer will increase leading to an increase in demand for HPV in developing countries coupled with awareness campaigns launched by governments.

Key Players Landscape and Outlook

Over the past few years, global human papillomavirus vaccine market has experienced a significant trend of mergers and collaborations among pharmaceutical companies and research institutions. These strategic partnerships have emerged as powerful drivers in advancing HPV vaccine development and distribution, with the shared goal of addressing the burden of HPV infections and associated diseases on a worldwide scale. The increasing demand for HPV vaccines, fueled by the growing awareness of their preventive benefits against cervical cancer and other HPV-related illnesses, has spurred key industry players to unite their efforts. Through mergers and collaborations, these companies combine their resources, expertise, and research capabilities to accelerate vaccine development, enhance formulations, and extend their reach in global human papillomavirus vaccine market.

For instance, in December 2022, NusaGard, a human papillomavirus (HPV) vaccination, was launched by Bio Farma Induk Holding BUMN Pharmacy in partnership with Merck Sharp & Dohme (MSD) and its subsidiaries, Kimia Farma and Indofarma.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Human Papillomavirus Vaccine Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. By Type
    • 4.2.1. Bivalent
    • 4.2.2. Quadrivalent
    • 4.2.3. Nonavalent
  • 4.3. By Disease indication
    • 4.3.1. Cervical cancer
    • 4.3.2. Anal cancer
    • 4.3.3. Vulvar & Vaginal cancer
    • 4.3.4. Penile cancer
    • 4.3.5. Oropharyngeal cancer
    • 4.3.6. Others
  • 4.4. By Method of Synthesis
    • 4.4.1. Nucleic acid-based
      • 4.4.1.1. DNA
      • 4.4.1.2. mRNA
    • 4.4.2. Peptide-based
    • 4.4.3. Protein-based
    • 4.4.4. Cell-based
    • 4.4.5. Live vector vaccine
  • 4.5. By Distribution Channel
    • 4.5.1. Hospital
    • 4.5.2. Retail Pharmacy
    • 4.5.3. Government Organizations
    • 4.5.4. Non-government Organizations
  • 4.6. By Region
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. South America
    • 4.6.4. Asia-Pacific
    • 4.6.5. Middle East and Africa
  • 4.7. By Company Market Share (%), 2023

5. Global Human Papillomavirus Vaccine Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. By Value
      • 5.1.1.2. By Volume
    • 5.1.2. By Type
      • 5.1.2.1. Bivalent
      • 5.1.2.2. Quadrivalent
      • 5.1.2.3. Nonavalent
    • 5.1.3. By Disease indication
      • 5.1.3.1. Cervical cancer
      • 5.1.3.2. Anal cancer
      • 5.1.3.3. Vulvar and Vaginal Cancer
      • 5.1.3.4. Penile Cancer
      • 5.1.3.5. Oropharyngeal Cancer
      • 5.1.3.6. Others
    • 5.1.4. By Method of Synthesis
      • 5.1.4.1. Nucleic acid-based
      • 5.1.4.1.1. DNA
      • 5.1.4.1.2. mRNA
      • 5.1.4.2. Peptide-based
      • 5.1.4.3. Protein-based
      • 5.1.4.4. Cell-based
      • 5.1.4.5. Live vector vaccine
    • 5.1.5. By Distribution Channel
      • 5.1.5.1. Hospital
      • 5.1.5.2. Retail Pharmacy
      • 5.1.5.3. Government Organizations
      • 5.1.5.4. Non-government Organizations
    • 5.1.6. United States*
      • 5.1.6.1. Market Size & Forecast
      • 5.1.6.1.1. By Value
      • 5.1.6.1.2. By Volume
      • 5.1.6.2. By Type
      • 5.1.6.2.1. Bivalent
      • 5.1.6.2.2. Quadrivalent
      • 5.1.6.2.3. Nonavalent
      • 5.1.6.3. By Disease Indication
      • 5.1.6.3.1. Cervical cancer
      • 5.1.6.3.2. Anal cancer
      • 5.1.6.3.3. Vulvar & Vaginal cancer
      • 5.1.6.3.4. Penile cancer
      • 5.1.6.3.5. Oropharyngeal Cancer
      • 5.1.6.3.6. Others
      • 5.1.6.4. By Method of synthesis
      • 5.1.6.4.1. Nucleic acid-based
      • 5.1.6.4.1.1. DNA
      • 5.1.6.4.1.2. mRNA
      • 5.1.6.4.2. Peptide-based
      • 5.1.6.4.3. Protein-based
      • 5.1.6.4.4. Cell-based
      • 5.1.6.4.5. Live vector vaccine
      • 5.1.6.5. By Distribution Channel
      • 5.1.6.5.1. Hospital
      • 5.1.6.5.2. Retail Pharmacy
      • 5.1.6.5.3. Government Organizations
      • 5.1.6.5.4. Non-government Organizations
    • 5.1.7. Canada
    • 5.1.8. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. South America
    • 5.3.1. Brazil
    • 5.3.2. Argentina
  • 5.4. Asia Pacific
    • 5.4.1. India
    • 5.4.2. China
    • 5.4.3. Japan
    • 5.4.4. Australia
    • 5.4.5. Vietnam
    • 5.4.6. South Korea
    • 5.4.7. Indonesia
    • 5.4.8. Philippines
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Type
  • 6.2. By Disease indication
  • 6.3. By Method of synthesis
  • 6.4. By Distribution channel
  • 6.5. By Region

7. Macro Environment and Industry Structure

  • 7.1. Supply Demand Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Clinical Trials
  • 9.2. Patent Landscape
  • 9.3. Regulatory Approvals
  • 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. GlaxoSmithKline PLC.
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Merck & Co., Inc.
  • 13.3. Beijing Health Guard Biotechnology, Inc.
  • 13.4. China National Biotec Group Company Limited
  • 13.5. Shanghai Bovax Biotechnology Co., Ltd.
  • 13.6. Walvax Biotechnology Co., Ltd
  • 13.7. Xiamen Innovax Biotech Co., Ltd.
  • 13.8. Serum Institute of India Pvt. Ltd.
  • 13.9. Eyegene Inc.
  • 13.10. Janssen Biotech, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

14. Strategic Recommendations

15. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 3. Global Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
  • Figure 4. Global Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
  • Figure 5. Global Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
  • Figure 6. Global Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 7. Global Human Papillomavirus Vaccine Market Share (%), By Region, 2017-2031F
  • Figure 8. North America Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
  • Figure 9. North America Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 10. North America Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
  • Figure 11. North America Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
  • Figure 12. North America Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
  • Figure 13. North America Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 14. North America Human Papillomavirus Vaccine Market Share (%), By Country, 2017-2031F
  • Figure 15. United States Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
  • Figure 16. United States Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 17. United States Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
  • Figure 18. United States Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
  • Figure 19. United States Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
  • Figure 20. United States Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 21. Canada Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
  • Figure 22. Canada Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 23. Canada Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
  • Figure 24. Canada Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
  • Figure 25. Canada Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
  • Figure 26. Canada Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 27. Mexico Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
  • Figure 28. Mexico Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 29. Mexico Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
  • Figure 30. Mexico Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
  • Figure 31. Mexico Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
  • Figure 32. Mexico Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 33. Europe Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
  • Figure 34. Europe Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 35. Europe Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
  • Figure 36. Europe Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
  • Figure 37. Europe Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
  • Figure 38. Europe Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 39. Europe Human Papillomavirus Vaccine Market Share (%), By Country, 2017-2031F
  • Figure 40. Germany Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
  • Figure 41. Germany Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 42. Germany Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
  • Figure 43. Germany Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
  • Figure 44. Germany Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
  • Figure 45. Germany Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 46. France Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. France Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 48. France Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
  • Figure 49. France Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
  • Figure 50. France Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
  • Figure 51. France Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 52. Italy Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
  • Figure 53. Italy Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 54. Italy Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
  • Figure 55. Italy Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
  • Figure 56. Italy Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
  • Figure 57. Italy Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 58. United Kingdom Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
  • Figure 59. United Kingdom Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 60. United Kingdom Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
  • Figure 61. United Kingdom Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
  • Figure 62. United Kingdom Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
  • Figure 63. United Kingdom Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 64. Russia Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
  • Figure 65. Russia Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 66. Russia Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
  • Figure 67. Russia Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
  • Figure 68. Russia Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
  • Figure 69. Russia Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 70. Netherlands Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
  • Figure 71. Netherlands Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 72. Netherlands Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
  • Figure 73. Netherlands Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
  • Figure 74. Netherlands Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
  • Figure 75. Netherlands Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 76. Spain Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
  • Figure 77. Spain Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 78. Spain Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
  • Figure 79. Spain Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
  • Figure 80. Spain Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
  • Figure 81. Spain Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 82. Turkey Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
  • Figure 83. Turkey Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 84. Turkey Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
  • Figure 85. Turkey Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
  • Figure 86. Turkey Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
  • Figure 87. Turkey Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 88. Poland Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
  • Figure 89. Poland Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 90. Poland Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
  • Figure 91. Poland Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
  • Figure 92. Poland Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
  • Figure 93. Poland Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 94. South America Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
  • Figure 95. South America Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 96. South America Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
  • Figure 97. South America Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
  • Figure 98. South America Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
  • Figure 99. South America Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 100. South America Human Papillomavirus Vaccine Market Share (%), By Country, 2017-2031F
  • Figure 101. Brazil Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
  • Figure 102. Brazil Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 103. Brazil Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
  • Figure 104. Brazil Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
  • Figure 105. Brazil Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
  • Figure 106. Brazil Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 107. Argentina Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
  • Figure 108. Argentina Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 109. Argentina Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
  • Figure 110. Argentina Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
  • Figure 111. Argentina Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
  • Figure 112. Argentina Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 113. Asia-Pacific Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
  • Figure 114. Asia-Pacific Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 115. Asia-Pacific Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
  • Figure 116. Asia-Pacific Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
  • Figure 117. Asia-Pacific Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
  • Figure 118. Asia-Pacific Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 119. Asia-Pacific Human Papillomavirus Vaccine Market Share (%), By Country, 2017-2031F
  • Figure 120. India Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
  • Figure 121. India Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 122. India Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
  • Figure 123. India Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
  • Figure 124. India Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
  • Figure 125. India Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 126. China Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
  • Figure 127. China Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 128. China Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
  • Figure 129. China Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
  • Figure 130. China Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
  • Figure 131. China Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 132. Japan Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
  • Figure 133. Japan Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 134. Japan Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
  • Figure 135. Japan Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
  • Figure 136. Japan Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
  • Figure 137. Japan Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 138. Australia Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
  • Figure 139. Australia Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 140. Australia Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
  • Figure 141. Australia Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
  • Figure 142. Australia Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
  • Figure 143. Australia Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 144. Vietnam Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
  • Figure 145. Vietnam Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 146. Vietnam Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
  • Figure 147. Vietnam Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
  • Figure 148. Vietnam Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
  • Figure 149. Vietnam Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 150. South Korea Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
  • Figure 151. South Korea Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 152. South Korea Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
  • Figure 153. South Korea Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
  • Figure 154. South Korea Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
  • Figure 155. South Korea Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 156. Indonesia Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
  • Figure 157. Indonesia Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 158. Indonesia Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
  • Figure 159. Indonesia Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
  • Figure 160. Indonesia Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
  • Figure 161. Indonesia Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 162. Philippines Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
  • Figure 163. Philippines Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 164. Philippines Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
  • Figure 165. Philippines Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
  • Figure 166. Philippines Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
  • Figure 167. Philippines Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 168. Middle East & Africa Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
  • Figure 169. Middle East & Africa Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 170. Middle East & Africa Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
  • Figure 171. Middle East & Africa Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
  • Figure 172. Middle East & Africa Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
  • Figure 173. Middle East & Africa Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 174. Middle East & Africa Human Papillomavirus Vaccine Market Share (%), By Country, 2017-2031F
  • Figure 175. Saudi Arabia Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
  • Figure 176. Saudi Arabia Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 177. Saudi Arabia Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
  • Figure 178. Saudi Arabia Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
  • Figure 179. Saudi Arabia Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
  • Figure 180. Saudi Arabia Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 181. UAE Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
  • Figure 182. UAE Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 183. UAE Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
  • Figure 184. UAE Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
  • Figure 185. UAE Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
  • Figure 186. UAE Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 187. South Africa Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
  • Figure 188. South Africa Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 189. South Africa Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
  • Figure 190. South Africa Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
  • Figure 191. South Africa Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
  • Figure 192. South Africa Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 193. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 194. By Disease Indication Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 195. By Method of Synthesis Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 196. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 197. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023